- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07742449
Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment (ejames3)
August 18, 2026 updated by: University of Oklahoma
This project will evaluate the feasibility and acceptability of Empowered Relief (ER) among American Indian adults who are currently receiving or have completed active cancer treatments at Stephenson Cancer Center (SCC).
ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors.
Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice.
ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment.
Because of its brief, didactic nature and Zoom delivery, ER can accommodate large class sizes and may address accessibility disparities among underserved cancer populations.
While ER is being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad, it has not been tested in American Indians with cancer.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jordan Keast
- Phone Number: 405-615-1474
- Email: jordan-keast@ou.edu
Study Locations
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- Stephenson Cancer Center - Tulsa Location
-
Contact:
- Sophia You
- Phone Number: 918-660-3925
- Email: dokyoung-you@ou.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Identifies as American Indian
- Has history of a cancer diagnosis
- Is currently undergoing or has completed active cancer treatment
- Experiences body pain most or every day
- Pain duration at least 3 months
- English fluency
Exclusion Criteria:
- Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the Zoom-based ER class)
- Life-threatening acute illness (e.g., infection, heart attack, injury)
- No access to a computer, a smartphone, or a tablet
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Empowered Relief
Participants in this arm will complete a 2-hour Empowered Relief pain management course and get access to all the course materials.
Participants will complete a series of follow-up surveys assessing the feasibility of the class for their pain intervention.
|
ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors.
Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice.
ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identify areas for cultural tailoring and improvement of ER
Time Frame: Assessed as part of the optional (n=30) Qualitative Post-class interview. (approx. 30 minutes)
|
We will use qualitative data from interviews to generate actionable recommendations to improve the cultural engagement, acceptability, and relevance of ER for American Indians with cancer.
|
Assessed as part of the optional (n=30) Qualitative Post-class interview. (approx. 30 minutes)
|
|
Feasibility of ER in American Indian populations
Time Frame: From participant accrual to the completion of their 3-mon follow up survey (approx. 4 months)
|
Indexed by:
Measures will be factored together to make an assessment on total feasibility. |
From participant accrual to the completion of their 3-mon follow up survey (approx. 4 months)
|
|
Pain Intensity
Time Frame: Data collected at the 1-, 2-, and 3-month follow up survey following the ER class
|
Pain intensity will be reported on a scale from 1-10, with 1 being "No Pain" and 10 being "Worst Pain Imaginable."
|
Data collected at the 1-, 2-, and 3-month follow up survey following the ER class
|
|
Pain Interference
Time Frame: Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
Pain interference will be gauged using a series of questions decerning the impact of the participants participants pain on daily activities.
Participants will rate the interference on a scale from 1-5, with 1 being "Not at All" and 5 being "Very Much."
|
Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
|
Emotional Distress
Time Frame: Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
Emotional distress will be measured using a series of questionnaires asking participants about the frequency of certain emotional reactions.
Participants will report frequency on a scale from 1-5, with 1 being "Never" and 5 being "Always."
|
Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
|
Sleep Disturbance
Time Frame: Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
Sleep Disturbance will be recorded using a series of questions rating the quality and frequency of sleep.
Participants will report on quality and frequency on a scale from 1-5, with 1 being "Very Poor/Not at All" and 5 being "Very Good/Very Much."
|
Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
|
Perceived Quality of Life
Time Frame: Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
Perceived Quality of Life will be reported on a scale from 1-5, with 1 being "Poor" and 5 being "Excellent."
|
Data collected at the 1-, 2-, and 3-month follow up survey following the ER class.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sophia You, University of Oklahoma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
July 20, 2026
First Submitted That Met QC Criteria
July 28, 2026
First Posted (Actual)
August 3, 2026
Study Record Updates
Last Update Posted (Actual)
August 20, 2026
Last Update Submitted That Met QC Criteria
August 18, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20065Ph1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.